Intravenous immunoglobulin–related hemolysis in patients treated for Kawasaki disease
Authors:
- 14 July 2015
- journal article
- case report
- Published by Wiley in Transfusion
- Vol. 55 (S2) , S90-S94
Abstract
BACKGROUND: Kawasaki disease (KD) is an idiopathic, multisystem disorder characterized by vasculitis of arteries, veins, and capillaries, affecting pediatric patients, and is the leading cause of acquired heart disease in childhood. The mainstays of therapy for KD are high‐dose intravenous immunoglobulin (IVIG) and aspirin, which are thought to prevent or modify the most serious cardiac sequelae. A well‐documented complication of high‐dose IVIG infusion in adults is hemolytic anemia due to passive transfer of anti‐A and anti‐B. Risk factors for hemolysis in another case series included patient blood group (group A, B, or AB), a high cumulative dose of IVIG, and concomitant inflammation documented by one or more markers like ferritin, fibrinogen, erythrocyte sedimentation rate, or C‐reactive protein.STUDY DESIGN AND METHODS: A 3‐year retrospective case review of patients previously recognized with apparent IVIG‐related hemolytic anemia identified by standard blood bank testing was performed at a tertiary care pediatric hospital.RESULTS: Five patients were identified with severe anemia each requiring RBC transfusion for anemia. All five patients demonstrated a positive direct antiglobulin testing. Four of five patients had anti‐A, anti‐B, and/or anti‐A1 with elution assays. All patients had signs of extravascular hemolysis with reticulocytosis, spherocytosis, and other hemolysis markers. One child died.CONCLUSION: Our cases represent dose‐dependent hemolysis caused by IVIG in association with severe anemia requiring transfusion with an average yearly incidence rate of 0.36%. Hemolysis is an underrecognized complication of IVIG administration. KD patients are at greater risk for anemia because of their lower baseline hemoglobin concentration, underlying acute inflammation, and oxygen requirements during acute illness.Keywords
This publication has 25 references indexed in Scilit:
- Kawasaki diseaseJournal of the American Academy of Dermatology, 2013
- Hemolytic anemia following intravenous immunoglobulin therapy in patients treated for Kawasaki disease: a report of 4 casesPediatric Rheumatology, 2012
- A pediatric case series of acute hemolysis after administration of intravenous immunoglobulinAmerican Journal of Hematology, 2009
- Intravenous immunoglobulin and salicylate differentially modulate pathogenic processes leading to vascular damage in a model of Kawasaki diseaseArthritis & Rheumatism, 2009
- Risks associated with the use of intravenous immunoglobulin 1 1This review article reflects the opinions of the authors and not necessarily those of the U.S. Food and Drug Administration.Transfusion Medicine Reviews, 2003
- Immune hemolysis, disseminated intravascular coagulation, and serum sickness after large doses of immune globulin given intravenously for Kawasaki diseaseThe Journal of Pediatrics, 1992
- Treatment of Kawasaki syndrome: A comparison of two dosage regimens of intravenously administered immune globulinThe Journal of Pediatrics, 1990
- Autoimmune hemolytic anemia in Kawasaki disease: a case reportTransfusion, 1990
- Massive Intravascular Hemolysis Associated with Intravenous Immunoglobulin in Bone Marrow Transplant RecipientsJournal of Pediatric Hematology/Oncology, 1988
- Autoimmune Hemolytic Anemia in Association with Kawasaki DiseaseJournal of Pediatric Hematology/Oncology, 1986